Amarin Corp Plc (AMRN)

[ranjo]

this is from declan on twits not sure if its been discussed

I am very surprised at the muted response, thus far, from investors and especially Amarin on the very positive development that CVS has added Vascepa exclusively to their formulary for 2022 at the expense of generics effective 1/1/22. Maybe Denner saw this coming or even had a hand to play here. This essentially renders generics obsolete and obviates any thinking Amarin needs to come up with their own generic equivalent. We don't know all the details on why this occured, but CVS says it's cost of brand Vascepa is comparable or less than generics. Did Amarin lower cost in US? If so, good move to squeeze out generics as legal issues unfold. Not a fan of JT, but he often said Vascepa is a volume play, not margins.
This ramps up volume and should see it reflected in scripts over next month or two.